New Drug Combo Shows Promise for Peyronie's Disease

Approximately one in ten men may develop Peyronie's disease in their lifetime, a condition marked by a curved penis during erection due to internal fibrous scar tissue, causing pain, sexual dysfunction, and severe psychological distress. New research, however, suggests an effective early-stage treatment may be possible by combining two well-known classes of drugs.

Researchers from Anglia Ruskin University and University College London Hospital tested a mix of phosphodiesterase type 5 (PDE5) inhibitors—such as sildenafil (Viagra) and tadalafil (Cialis)—with selective estrogen receptor modulators (SERMs), including tamoxifen. The findings indicate this combination could help slow or halt the disease's progression when used early.

Promising Clinical Results

The clinical trial involved 133 men with acute-phase Peyronie's disease who received the combined therapy for three months. Their outcomes were compared to a control group receiving standard care, which included vitamin E or no treatment, without any surgical intervention.

Results showed that 43% of patients in the combination therapy group saw improvement in penile curvature—nearly three times the rate recorded in the standard care group (15%). Pain during erections also dropped dramatically, falling from 65% to 1.5% in the combination group, compared to a decline from 50% to 27% in the other group.

Laboratory Foundation

These findings build on earlier laboratory research at Anglia Ruskin University, where scientists screened thousands of approved drugs to identify those capable of stopping fibroblasts from transforming into cells responsible for fibrosis—the root cause of Peyronie's disease. PDE5 inhibitors and SERMs emerged as the most effective compounds, particularly when used together, showing a stronger effect than either drug alone.

The researchers note that no approved oral treatments currently exist to halt the disease's progression in its early stages, often leaving patients in a waiting period until symptoms stabilize before turning to options like injections or surgery.

New Treatment Horizons

The scientists described the preliminary results as encouraging, stating that repurposing known and safe drugs could accelerate the development of new treatments for fibrotic diseases. The research team explained that combining these two drug types may represent a significant shift in understanding the disease—moving from merely managing symptoms to influencing its underlying mechanism—while stressing the need for larger studies to confirm the results before formal adoption of the therapy.

The study was published in the Journal of Sexual Medicine.